Skip to Content

ALPS Medical Breakthroughs ETF SBIO

Medalist Rating as of | See ALPS Investment Hub
  • NAV / 1-Day Return 34.59  /  +0.40 %
  • Total Assets 110.7 Mil
  • Adj. Expense Ratio
    0.500%
  • Expense Ratio 0.500%
  • Distribution Fee Level
  • Share Class Type
  • Category Health
  • Investment Style Small Growth
  • Min. Initial Investment
  • Status Open
  • TTM Yield 0.22%
  • Turnover 81%

USD | NAV as of May 08, 2024 | 1-Day Return as of May 08, 2024, 12:24 AM GMT+0

Morningstar’s Analysis SBIO

Will SBIO outperform in future?

Get our overall rating based on a fundamental assessment of the pillars below.

Weakness in ALPS Medical Breakthroughs ETF's People and Process Pillar ratings limits this strategy to a Morningstar Medalist Rating of Negative.

null Morningstar Manager Research

Morningstar Manager Research

Summary

The portfolio maintains a sizable cost advantage over competitors, priced within the cheapest fee quintile among peers.

Rated on Published on

Unlock our full analysis with Morningstar Investor

Portfolio Holdings SBIO

  • Current Portfolio Date
  • Equity Holdings
  • Bond Holdings
  • Other Holdings
  • % Assets in Top 10 Holdings 32.7
Top 10 Holdings
% Portfolio Weight
Market Value USD
Sector

Viking Therapeutics Inc

5.19 5.7 Mil
Healthcare

Cerevel Therapeutics Holdings Inc Ordinary Shares

4.88 5.4 Mil
Healthcare

Vaxcyte Inc Ordinary Shares

4.54 5.0 Mil
Healthcare

Revolution Medicines Inc Ordinary Shares

4.07 4.5 Mil
Healthcare

Alpine Immune Sciences Inc

2.68 3.0 Mil
Healthcare

Alkermes PLC

2.54 2.8 Mil
Healthcare

Crinetics Pharmaceuticals Inc

2.29 2.5 Mil
Healthcare

Axsome Therapeutics Inc

2.28 2.5 Mil
Healthcare

SpringWorks Therapeutics Inc Ordinary Shares

2.16 2.4 Mil
Healthcare

Xenon Pharmaceuticals Inc

2.06 2.3 Mil
Healthcare